Active substanceButamateButamate Similar drugsTo uncover Codelac® Neo pills inwards OTISIFARM, OJSC Russia Codelac® Neo syrup inwards OTISIFARM, OJSC Russia Codelac® Neo drops inwards OTISIFARM, OJSC Russia Omnitus pills inwards Hemofarm AD Serbia Omnitus syrup inwards Hemofarm AD Serbia Panathus® pills inwards KRKA, dd, Novo mesto, AO Panathus® syrup inwards KRKA, dd, Novo mesto, AO Panathus® Forte syrup inwards KRKA, dd, Novo mesto, AO Panathus® Forte pills inwards KRKA, dd, Novo mesto, AO Synecode® drops inwards d / children Новартис Консьюмер Хелс СА Switzerland Synecode® syrup inwards Новартис Консьюмер Хелс СА Switzerland Dosage form: & nbspSyrup. Composition:To 5 ml of syrup Active substance:Butamirate citrate 4.00 mg.Excipients: citric acid, monohydrate 12.50 mg, sorbitol, liquid 1750.00 mg, glycerol 1250.00 mg, sodium saccharin 6.25 mg, sodium benzoate 5.00 mg, flavoring lemon 10.00 mg, sodium hydroxide 2.50 mg , water, purified to 5,00 ml. Description:Transparent liquid from colorless to light yellow color with a characteristic smell of lemon. Pharmacotherapeutic group:Antitussive remedy of central action. ATX: & nbspR.05.D.B.13 Butamate Pharmacodynamics:Butamate - the active substance of the drug Panathus, is a central antitussive drug that does not belong to the alkaloids of opium, either chemically or pharmacologically. Suppresses cough, having direct influence on the cough center.Has a bronchodilating effect. Promotes respiration, improving spirometry (reduces airway resistance) and oxygenation of the blood. Pharmacokinetics:Butamate quickly and completely absorbed when taken orally. After taking 150 mg of butamirate, the maximum concentration in the blood plasma of the main metabolite (2-phenylbutyric acid) is reached after approximately 1.5 hours and is 6.4 μg / ml. With repeated use of butamirate, its concentration in the blood plasma remains linear and cumulation of ns is observed.Hydrolysis of butamate, initially to 2-phenylbutyric acid and diethylaminoethoxyethanol, begins in the blood. These metabolites also have antitussive activity. Butamate and its metabolites have almost the maximum (about 95%) degree of binding to plasma proteins, which causes their long half-life (T1/2) and prolonged antitussive action. Metabolites are excreted mainly by the kidneys, and metabolites with acid reaction are largely associated with glucuronic acid. T1/2 is 6 hours. Indications:Dry cough of any etiology, including pertussis, for suppressing cough in the preoperative and postoperative period, with surgical interventions and bronchoscopy. Contraindications:Hypersensitivity to the components of the drug, pregnancy (I trimester), the period of breastfeeding, children under 3 years of age, fructose intolerance. Carefully:Pregnancy (II-III trimesters). Pregnancy and lactation:There is no data on the safety of the use of the drug Panathus during pregnancy and its passage through the placental barrier. The drug is not recommended for use in the first trimester of pregnancy. In the II and III trimesters of pregnancy, the drug can be used only after consulting a doctor. Given the lack of data on the isolation of butramate in breast milk, the use of the drug Panathus during breastfeeding nt is recommended. Dosing and Administration:Inside, before eating.Children from 3 to 6 years: 10 ml 3 times a day; children from 6 to 9 years: 15 ml 3 times a day; children from 9 to 12 years and older: 15 ml 4 times a day; adults: 30 ml 3-4 times a day. Use a measuring spoon (supplied). 1 measuring spoon = 5 ml.If cough persists for more than 5-7 days, you should consult a doctor. Side effects:Classification of the frequency of development of side effects of the World Health Organization (WHO):very often ≥ 1/10often from≥1 / 100 to <1/10infrequently from ≥ 1/1000 to <1/100rarely from ≥1 / 10000 to <1/1000very rarely from ≥ 1/100000, including individual messages.From the central nervous system (CNS): rarely: drowsiness, dizziness.From the digestive system: rarely: nausea, vomiting, diarrhea.From the skin: rarely: exanthema.Other: possible the development of allergic reactions. Overdose:Symptoms: drowsiness, dizziness, nausea, vomiting, abdominal pain, diarrhea, irritability, impaired coordination of movements, lowering of blood pressure.Treated: rinse the stomach, prescribe Activated carbon, laxatives, as well as carry out activities to maintain the function of the cardiovascular and respiratory systems. There is no antidote. Treatment is symptomatic. Interaction:No drug interactions for butamir are described.Due to butamate suppresses the cough reflex, simultaneous use of expectorants should be avoided in order to avoid congestion of sputum in the respiratory tract.During the period of application of the drug Panathus, the use of ethanol, as well as drugs depressing the central nervous system (hypnotics, neuroleptics, tranquilizers, etc.) is not recommended. Special instructions:The preparation of Panathus contains as sweeteners saccharin sodium and sorbitol, so it can be used in patients with diabetes mellitus.5 ml of syrup (1 measuring spoon) contain 1.75 g of sorbitol. For each single dose, the patient receives either 10.5 g of sorbitol (6 scoops), or 5.25 g of sorbitol (3 scoops), or 3.5 g of sorbitol (2 scoops).The drug Panathus is not used in patients with fructose intolerance.If the cough does not stop after 5-7 days of using the product, consult a doctor. Effect on the ability to drive transp. cf. and fur:The drug Panathus can cause drowsiness, so you need to be careful when driving vehicles and working with complex technical devices that require increased concentration and speed of psychomotor reactions. Form release / dosage:Syrup, 4 mg / 5 ml. Packaging:200 ml of syrup in a vial of dark glass, sealed with a plastic stopper with a dissector of liquid and a plastic lid with the control of the first opening.1 bottle is placed in a pack of cardboard along with a measuring spoon and instructions for use. Storage conditions:At a temperature of no higher than 25 ° C, in the original packaging.Keep out of the reach of children. Shelf life:4 years.Do not use the drug after the expiration date. Terms of leave from pharmacies:Without recipe Registration number:П N012677 / 02 Date of registration:26.03.2012 / 30.10.2015 Expiration Date:Unlimited The owner of the registration certificate:KRKA, dd, Novo mesto, AOKRKA, dd, Novo mesto, AO Manufacturer: & nbspKRKA, dd, Novo mesto, AO Slovenia Representation: & nbspKRKA, dd, Novo mesto, AOKRKA, dd, Novo mesto, AO Information update date: & nbsp2016-12-14 Illustrated instructions × Illustrated instructions Instructions